Human pyrimidine receptor
This invention provides a receptor having a preference for pyrimidine nucleotides preferably uridine triphosphate over purine nucleotides. A receptor having a preference for pyrimidine nucleotides over purine nucleotides means a receptor for which pyrimidine nucleotides and purine nucleotides are not equally active and equipotent. This means that the receptor according to the invention in presence of these agonists presents a functional response (preferably the accumulation of Inositol triphosphate (IP3), diacylglycerol (DAG), or calcium ions) to lower concentration of pyrimidine nucleotides, preferably uridine triphosphate, than to purine nucleotides or a more important functional response to similar concentration of pyrimidine nucleotide than to purine nucleotide
1. A method for determining whether a ligand can specifically bind to a receptor, wherein said receptor comprises the amino acid sequence shown in SEQ ID NO:2, comprising the following steps:
i) preparing a cell extract from cells transfected with an expression vector comprising the nucleic acid molecule encoding said receptor,
ii) isolating a membrane fraction from the cell extract,
iii) contacting the ligand with the membrane fraction under conditions permitting binding of the ligand to said receptor, and
iv) detecting the presence or absence of the ligand bound specifically to said receptor, wherein the presence of the ligand indicates that the ligand can specifically bind to said receptor.
2. The method of claim 1 , wherein said receptor consists of the amino acid sequence shown in SEQ ID NO:2.